

LRRC6 siRNA (m): sc-149098

BACKGROUND

Leucine-rich repeats (LRRs) are 20-29 amino acid motifs that mediate protein-protein interactions. The primary function of these motifs is to provide a versatile structural framework for the formation of these protein-protein interactions. LRRs are present in a variety of proteins with diverse structure and function, including innate immunity and nervous system development. Several human diseases are associated with mutation in the genes encoding LRR-containing proteins. The leucine-rich repeat and fibronectin type-III domain-containing protein 62 (LRRC62), also designated extracellular leucine-rich repeat and fibronectin type III domain-containing protein 2 (ELFN2), is a 820 amino acid protein that contains five LRR repeats. The gene encoding LRRC62 maps to chromosome 22q13.1, which contains over 500 genes and about 49 million bases. Translocations between chromosomes 9 and 22 may lead to the formation of the Philadelphia chromosome and the subsequent production of the novel fusion protein, Bcr-Abl, a potent cell proliferation activator found in several types of leukemia.

REFERENCES

1. Gilbert, F. 1998. Disease genes and chromosomes: disease maps of the human genome. *Chromosome 22. Genet. Test.* 2: 89-97.
2. Kobe, B. and Kajava, A.V. 2001. The leucine-rich repeat as a protein recognition motif. *Curr. Opin. Struct. Biol.* 11: 725-732.
3. Tsilchorozidou, T., Menko, F.H., Laloo, F., Kidd, A., De Silva, R., Thomas, H., Smith, P., Malcolmson, A., Dore, J., Madan, K., Brown, A., Yovos, J.G., Tsaligopoulos, M., Vogiatzis, N., Baser, M.E., Wallace, A.J., et al. 2004. Constitutional rearrangements of chromosome 22 as a cause of neurofibromatosis 2. *J. Med. Genet.* 41: 529-534.
4. Matsushima, N., Tachi, N., Kuroki, Y., Enkhbayar, P., Osaki, M., Kamiya, M. and Kretsinger, R.H. 2005. Structural analysis of leucine-rich-repeat variants in proteins associated with human diseases. *Cell. Mol. Life Sci.* 62: 2771-2791.
5. Chen, Y., Aulia, S., Li, L. and Tang, B.L. 2006. AMIGO and friends: an emerging family of brain-enriched, neuronal growth modulating, type I transmembrane proteins with leucine-rich repeats (LRR) and cell adhesion molecule motifs. *Brain Res. Rev.* 51: 265-274.
6. Zheng, X., Güller, S., Beissert, T., Puccetti, E. and Ruthardt, M. 2006. Bcr and its mutants, the reciprocal t(9;22)-associated Abl/Bcr fusion proteins, differentially regulate the cytoskeleton and cell motility. *BMC Cancer* 6: 262.
7. Hay, B.N. 2007. Deletion 22q11: spectrum of associated disorders. *Semin. Pediatr. Neurol.* 14: 136-139.
8. Dolan, J., Walshe, K., Alsbury, S., Hokamp, K., O'Keeffe, S., Okafuji, T., Miller, S.F., Tear, G. and Mitchell, K.J. 2007. The extracellular leucine-rich repeat superfamily; a comparative survey and analysis of evolutionary relationships and expression patterns. *BMC Genomics* 8: 320.
9. Ko, J. and Kim, E. 2007. Leucine-rich repeat proteins of synapses. *J. Neurosci. Res.* 85: 2824-2832.

CHROMOSOMAL LOCATION

Genetic locus: *Lrrc6* (mouse) mapping to 15 D2.

PRODUCT

LRRC6 siRNA (m) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see LRRC6 shRNA Plasmid (m): sc-149098-SH and LRRC6 shRNA (m) Lentiviral Particles: sc-149098-V as alternate gene silencing products.

For independent verification of LRRC6 (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-149098A, sc-149098B and sc-149098C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

LRRC6 siRNA (m) is recommended for the inhibition of LRRC6 expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor LRRC6 gene expression knockdown using RT-PCR Primer: LRRC6 (m)-PR: sc-149098-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.